Wall Street Zen Upgrades LENSAR (NASDAQ:LNSR) to Buy

LENSAR (NASDAQ:LNSR) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Sunday.

Other equities analysts also recently issued research reports about the company. Lake Street Capital restated a “buy” rating and issued a $13.00 target price on shares of LENSAR in a research note on Thursday, August 13th. BTIG Research increased their price target on LENSAR from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of LENSAR in a report on Friday, August 7th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, LENSAR presently has an average rating of “Hold” and a consensus price target of $11.50.

LENSAR Price Performance

NASDAQ LNSR opened at $9.23 on Friday. LENSAR has a 1 year low of $4.95 and a 1 year high of $12.95. The firm has a market cap of $113.44 million, a price-to-earnings ratio of -27.97 and a beta of 0.89. The company has a fifty day moving average price of $6.23 and a 200-day moving average price of $7.17.

LENSAR (NASDAQ:LNSR) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.26. LENSAR had a net margin of 57.57% and a negative return on equity of 529.08%. The company had revenue of $16.50 million for the quarter, compared to analyst estimates of $14.65 million.

Institutional Trading of LENSAR

Several hedge funds have recently made changes to their positions in the company. Credit Industriel ET Commercial grew its stake in shares of LENSAR by 0.8% during the 4th quarter. Credit Industriel ET Commercial now owns 124,483 shares of the company’s stock worth $1,448,000 after acquiring an additional 1,000 shares during the period. BNP Paribas Financial Markets raised its stake in LENSAR by 129.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock valued at $25,000 after acquiring an additional 1,131 shares during the period. JPMorgan Chase & Co. raised its stake in LENSAR by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,928 shares of the company’s stock valued at $73,000 after acquiring an additional 1,254 shares during the period. Barclays PLC lifted its holdings in LENSAR by 10.3% during the fourth quarter. Barclays PLC now owns 14,857 shares of the company’s stock valued at $173,000 after purchasing an additional 1,389 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in LENSAR by 0.3% during the third quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock valued at $6,269,000 after purchasing an additional 1,446 shares during the last quarter. 40.15% of the stock is currently owned by institutional investors.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.